Breaking news today on ENDPOINTS NEWS.COM. Apart from me, is anyone else suspicious about this? He has been recently accused of being a bit too close to Big Pharma Companies such as Pfizer and Biogen. I don't know how long he was with the FDA , but I would hate to think he was there when PBT2 was rejected for "poor trial design" and the bogus "dog studies debacle." With his dubious integrity perhaps in question, I guess we shouldn't hire him to lead our new company that MAY BE FORMED to pursue PBT2 for both antibiotic resistance and Alzheimer's Disease?! Regardless of honesty and integrity being rather important, how would we pay such a high-powered, experienced, neuroscience "expert?" Maybe Billy will show up soon with a new job at Pfizer, Biogen, or even with "The FUND"! I sure hope not...
- Forums
- ASX - By Stock
- ATH
- ABRUPT, IMMEDIATE DEPARTURE OF BILLY DUNN, FDA NEUROSCIENCE CHIEF
ABRUPT, IMMEDIATE DEPARTURE OF BILLY DUNN, FDA NEUROSCIENCE CHIEF
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ATH (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $31.42M |
Open | High | Low | Value | Volume |
0.6¢ | 0.7¢ | 0.6¢ | $113.4K | 18.91M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
60 | 62614132 | 0.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.6¢ | 3049506 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
60 | 62614132 | 0.005 |
59 | 71509382 | 0.004 |
52 | 50331648 | 0.003 |
15 | 32945514 | 0.002 |
13 | 94865101 | 0.001 |
Price($) | Vol. | No. |
---|---|---|
0.006 | 3049506 | 2 |
0.007 | 16412773 | 18 |
0.008 | 21425596 | 29 |
0.009 | 11294412 | 13 |
0.010 | 3740594 | 9 |
Last trade - 16.10pm 29/04/2024 (20 minute delay) ? |
|
|||||
Last
0.6¢ |
  |
Change
0.000 ( 0.00 %) |
|||
Open | High | Low | Volume | ||
0.6¢ | 0.6¢ | 0.6¢ | 3890928 | ||
Last updated 15.43pm 29/04/2024 ? |
Featured News
ATH (ASX) Chart |